Breast cancer organoids derived from patients: A platform for tailored drug screening
Biochemical Pharmacology · 2023-11 · 217 · 115803
DOI: 10.1016/j.bcp.2023.115803 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023-11. Verfasst von Yen-Dun Tony Tzeng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biomedical Sciences, National Sun Yat-sen University,…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer stands as the most prevalent and heterogeneous malignancy affecting women globally, posing a substantial health concern. Enhanced comprehension of tumor pathology and the development of novel therapeutics are pivotal for advancing breast cancer treatment. Contemporary breast cancer investigation heavily leans on in vivo models and conventional cell culture techniques. Nonetheless, these approaches often encounter high failure rates in clinical trials due to species disparities and tissue structure variations. To address this, three-dimensional cultivation of organoids, resembling organ-like structures, has emerged as a promising alternative. Organoids represent innovative in vitro models that mirror in vivo tissue microenvironments. They retain the original tumor's diversity and facilitate the expansion of tumor samples from diverse origins, facilitating the representation of varying tumor stages. Optimized breast cancer organoid models, under precise culture conditions, offer benefits including convenient sample acquisition, abbreviated cultivation durations, and genetic stability. These attributes ensure a faithful replication of in vivo traits of breast cancer cells. As intricate cellular entities boasting spatial arrangements, breast cancer organoid models harbor substantial potential in precision medicine, organ transplantation, modeling intricate diseases, gene therapy, and drug innovation. This review delivers an overview of organoid culture techniques and outlines future prospects for organoid modeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
- Department of Surgery, Kaohsiung Municipal Minsheng Hospital, Kaohsiung, Taiwan.
- School of Medicine, National Yang-Ming University, Taipei 112, Taiwan; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112, Taiwan. Electronic address: lmtseng@vghtpe.gov.tw.
- Division of Breast Surgery, Department of Surgery, Center for Cancer Research, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung 807, Taiwan. Electronic address: mifeho@kmu.edu.tw.
- Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Electronic address: c…
Zitieren
APA
Tzeng, Y. T., Hsiao, J. H., Tseng, L. M., Hou, M. F., & Li, C. J. (2023). Breast cancer organoids derived from patients: A platform for tailored drug screening. Biochemical Pharmacology, 217, 115803. https://doi.org/10.1016/j.bcp.2023.115803
Vancouver
Tzeng YT, Hsiao JH, Tseng LM, Hou MF, Li CJ. Breast cancer organoids derived from patients: A platform for tailored drug screening. Biochemical Pharmacology. 2023;217:115803. doi:10.1016/j.bcp.2023.115803
BibTeX
@article{Tzeng2023,
author = {Tzeng, Yen-Dun Tony and Hsiao, Jui-Hu and Tseng, Ling-Ming and Hou, Ming-Feng and Li, Chia-Jung},
title = {Breast cancer organoids derived from patients: A platform for tailored drug screening},
journal = {Biochemical Pharmacology},
year = {2023},
volume = {217},
pages = {115803},
doi = {10.1016/j.bcp.2023.115803}
}
EUVIMED